Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Essent Biologics debuts stem cell offerings for biopharma and cell therapy research

By Brian Buntz | June 28, 2021

Essent BiologicsAlloSource (Centennial, Colo.), a central U.S. provider of allograft providers, has founded a separate nonprofit known as Essent Biologics to provide human-derived biomaterials for research. Essent has recently launched a human mesenchymal stem cells (hMSCs) offering for a range of research applications. 

“The mission for the nonprofit is to maximize that gift of donation,” said Derek Mathers, head of business development at Essent Biologics. 

Each vial of hMSCs contains more than one million cells after thawing. They have a passage level of P0 or P1 to ensure potency.

The company offers stem cells produced under current Good Manufacturing Practices (cGMP) and in accordance with International Society for Cell & Gene Therapy (ISCT) guidelines. 

The company’s scientists have discovered a method for isolating cells and scaffold materials from tissue donation. The resulting cells are the first human-derived cell product that doesn’t use animal products or antibiotics in their processing, Mathers said. 

From a single donation, Essent Biologics can produce approximately 1.5 billion primary cells, and approximately 1 kg of scaffold materials for regenerative medicine purposes.

Essent can provide information about the origin of stem cells. “Traditionally, it’s been very difficult to tell exactly what donor human mesenchymal stem cells came from,” Mathers explained. “Our whole vision is to pair real human tissue from the donor with comprehensive donor information but still protect that donor’s identity,” he said. 

Essent can specify, for instance, if a donor was a smoker, their BMI and lifestyle factors, and whether they had any specific diseases. “We typically provide healthy cells,” but human disease tissue can potentially enable researchers to reduce or eliminate the need for testing with animal products. “Human cells are the most relevant biology for human therapies that they’re developing,” Mathers concluded. 


Filed Under: Drug Discovery, Drug Discovery and Development
Tagged With: allograft, AlloSource, biomaterials, cGMP, Essent Biologics, Good Manufacturing Practices, hMSCs, human mesenchymal stem cells
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Lab facility
Massachusetts is competing for ARPA-H biomedical research center
Blockchain
Startup vies to get blockchain adoption in pharma off the ground
Black Diamond Therapeutics
Black Diamond analysis highlights 22 new oncogenic HER2 driver mutations
NIH National Institutes of Health
NIH licenses COVID-19 research technologies to WHO initiative

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50